Kopran Ltd, a Parijat Enterprises pharma company, suffered heavy setback during the year ended March 2005 and it incurred a net loss of Rs 35.48 crore as against a small net profit of Rs 0.69 crore in the previous year. The company's sales declined by 29 per cent to Rs 99.08 crore from Rs 139.60 crore. Further, its other income moved down to Rs 1.63 crore from Rs 29.37 crore in the previous period.

Though the pharmaceutical sales increased to Rs 99.98 crore from Rs 90.94 crore, its trading activity was completely stopped during 2004-05. The sales of domestic formulations were significantly affected due to the resistance of trade to buy during last quarter of the 2004-05 on account of implication of VAT.

Due to amalgamation of Kopran Pharmaceuticals Ltd with Kopran Ltd. The company allotted 40.80 lakh equity shares of Rs 10 each to the shareholders of erstwhile Kopran Pharmaceutical Ltd. Due to this allotment of shares, the equity capital of the company increased to Rs 25.51 crore from Rs 21.43 crore in the previous year. Meanwhile, Kopran Ltd has allotted 30 lakh warrants to Sampada Chemicals Ltd.